Evidence map›Paper›PMID 34204485›Full record

ReviewCells2021

Strength and Numbers: The Role of Affinity and Avidity in the 'Quality' of T Cell Tolerance.

Sébastien This, Stefanie F Valbon, Marie-Ève Lebel, Heather J Melichar

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sébastien ThisCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.ORCID 0000-0003-2931-9050
Stefanie F ValbonCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.
Marie-Ève LebelCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.
Heather J MelicharCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.
Hôpital Maisonneuve-Rosemont · CA

Funding

CIHR PJT-168862
6 · The paper itself

Abstract

The ability of T cells to identify foreign antigens and mount an efficient immune response while limiting activation upon recognition of self and self-associated peptides is critical. Multiple tolerance mechanisms work in concert to prevent the generation and activation of self-reactive T cells. T cell tolerance is tightly regulated, as defects in these processes can lead to devastating disease; a wide variety of autoimmune diseases and, more recently, adverse immune-related events associated with checkpoint blockade immunotherapy have been linked to a breakdown in T cell tolerance. The quantity and quality of antigen receptor signaling depend on a variety of parameters that include T cell receptor affinity and avidity for peptide. Autoreactive T cell fate choices (e.g., deletion, anergy, regulatory T cell development) are highly dependent on the strength of T cell receptor interactions with self-peptide. However, less is known about how differences in the strength of T cell receptor signaling during differentiation influences the 'function' and persistence of anergic and regulatory T cell populations. Here, we review the literature on this subject and discuss the clinical implications of how T cell receptor signal strength influences the 'quality' of anergic and regulatory T cell populations.

Indexed as

AnimalsCell DifferentiationClonal AnergyHumansSelf ToleranceT-Lymphocytesaffinityanergyavidityheterogeneityimmunotherapyregulatory T cells (Treg)T cell receptor signalingT cellstolerance

Identifiers

PMID34204485
PMCPMC8234061
OpenAlexW3168980228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.